Pharmaceutical Technology

FEBRUARY 13, 2023

SOPHiA GENETICS is expanding its collaboration with AstraZeneca to include multimodal approaches for developing cancer drugs. This collaboration aims to use the global SOPHiA DDM platform, a cloud-native platform of SOPHiA GENETICS, and multimodal algorithmic capabilities for AstraZeneca’s oncology portfolio.

Genetics 130

Genetics Development Drugs Genome 130

Pharmaceutical Technology

SEPTEMBER 15, 2023

Cure Genetics has entered a partnership and licensing deal with Frametact to develop gene therapy for familial neurological ailments.

Genetics 246

Genetics Gene Gene Therapy Licensing 246

Pharmaceutical Technology

MARCH 1, 2024

1910 Genetics has entered an agreement with Microsoft, aiming to revitalise pharmaceutical research and development (R&D) productivity.

Genetics 130

Genetics Production Development Research 130

Bio Pharma Dive

FEBRUARY 23, 2023

Graphite Bio and Sangamo are stopping work on their respective sickle cell gene therapies, while Intellia revealed partner Novartis ended development of its genetic treatment for the blood disease.

Gene Therapy 257

Gene Therapy Gene Development Genetics 257

Bio Pharma Dive

SEPTEMBER 14, 2020

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020.

Genetics 297

Genetics Antibody Drugs Development 297

Pharmaceutical Technology

OCTOBER 25, 2022

Ast ellas Pharma has announced plans to make a strategic investment to back the development of Taysha Gene Therapies’ adeno-associated virus (AAV) development programmes for Rett syndrome and giant axonal neuropathy (GAN). This would allow the companies to boost the development of new therapy options for Rett syndrome and GAN patients.

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

Pharma Mirror

APRIL 28, 2021

Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the U.S. and Europe. Catalent will further support process optimization and look to reduce material.

Gene Therapy 130

Gene Therapy Genetic Disease Genetics Gene 130

Medical Xpress

MAY 16, 2023

However, how the brain has developed over the course of evolution and which genes are responsible for the high cognitive abilities is still largely unclear. The better our understanding of the role of genes in brain development, the more likely it will be that we will be able to develop treatments for serious brain diseases.

Development 119

Development Genetics Gene Research 119

Medical Xpress

MARCH 14, 2023

National Institutes of Health researchers compared a new genetic animal model of Down syndrome to the standard model and found the updated version to be enhanced. The results of this study, published in Biological Psychiatry, may help researchers develop more precise treatments to improve cognition in people with Down syndrome.

Genetics 72

Genetics Development Research 72

Pharmaceutical Technology

DECEMBER 20, 2023

LC-002 is under clinical development by Genetic Immunity and currently in Phase II for Human Immunodeficiency Virus (HIV) Infections (AIDS).

Genetics 100

Genetics Clinical Development Development 100

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Genetically modified animal models. Regeneron Pharmaceuticals is one of the leading patent filers in the generation of genetically modified animal models.

Genetics 130

Genetics DNA Antibody Genome 130

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Pharmaceutical Technology

OCTOBER 19, 2022

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss.

Gene Therapy 298

Gene Therapy Gene Development Genetics 298

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

Pharmaceutical Technology

JUNE 4, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors for genetically modified cells. However, not all innovations are equal and nor do they follow a constant upward trend.

Genetics 130

Genetics Gene Expression DNA Antibody 130

Worldwide Clinical Trials

FEBRUARY 6, 2023

When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed. Read the full article!

Genetics 130

Genetics Clinical Trials Clinical Trials Genotype 130

Outsourcing Pharma

JANUARY 23, 2024

Sano Genetics says it is developing software that will enable âthe precision medicine revolutionâ and has raised $11.4 million in new funding.

Genetics 86

Genetics Medicine Development Drug Delivery 86

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 256

Gene Therapy Gene Development Manufacturing 256

pharmaphorum

JUNE 9, 2023

3rd Rare & Genetic Kidney Disease Drug Development Summit Mike.Hammerton Fri, 09/06/2023 - 07:13 Bookmark this

Genetics 52

Genetics Development Drugs 52

Scienmag

MARCH 30, 2022

Mineral systems: Their advantages in terms of developing holistic genetic models and for target generation in global mineral exploration Credit: GeoGeo Mineral systems: Their advantages in terms of developing holistic genetic models and for target generation in global mineral exploration [link] Announcing a new publication for Geosystems and Geoenvironment (..)

Genetics 89

Genetics Development Engineer 89

BioPharma Reporter

FEBRUARY 21, 2023

The Danish-US biotech Hemab Therapeutics bags $135m to finance the clinical development of prophylactic treatments for genetic bleeding disorders including Glanzmann thrombasthenia and von Willebrand disease.

Genetics 122

Genetics Clinical Development Development 122

Pharmaceutical Technology

FEBRUARY 9, 2023

The collaboration is aimed at discovering and developing new advanced treatments for genitourinary (GU) tumours as well as other related serious diseases using ReviR’s RNA-targeted technologies. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

APRIL 26, 2023

MiNA Therapeutics has entered into a research collaboration and option licensing agreement with BioMarin Pharmaceutical to speed up the development of therapeutic ribonucleic acid activation (RNAa) candidates to treat rare genetic diseases. BioMarin may then license the assets fully to develop and commercialise them across the globe.

Development 130

Development Genetic Disease Genetics Gene Therapy 130

STAT News

DECEMBER 10, 2022

NEW ORLEANS — An emerging class of genetically targeted drugs is inducing remissions in about one-third of patients with advanced leukemia, according to updates Saturday from separate clinical trials. Continue to STAT+ to read the full story…

Genetics 141

Genetics Drugs Clinical Trials Clinical Trials 141

Bio Pharma Dive

APRIL 1, 2022

Taysha Gene Therapies is narrowing its research efforts and cutting around 35% of its workforce, the latest in a series of layoffs announced by makers of genetic medicines.

Gene Therapy 275

Gene Therapy Gene Development Genetics 275

pharmaphorum

JANUARY 24, 2023

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Genetics 96

Genetics Drugs Genome Project Biobanking 96

Roots Analysis

JANUARY 19, 2024

Introduction In a strategic move to accelerate the development and launch of genetic medicines, BridgeBio Pharma has successfully secured up to USD 1.25 Billion to Propel Genetic Medicine Development appeared first on Blog. billion from Blue Owl Capital and Canada Pension Plan Investment Board.

Genetics 40

Genetics Medicine Development Sales 40

Pharma Mirror

FEBRUARY 23, 2021

Catalent is also announcing the launch of pDNA development and manufacturing services at its Rockville, Maryland facility. The post Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site appeared first on Pharma Mirror Magazine. SOMERSET, N.J. SOMERSET, N.J.

Genetics 130

Genetics Manufacturing Gene Therapy DNA 130

Medical Xpress

FEBRUARY 21, 2023

Researchers from Children's Hospital of Philadelphia (CHOP) developed two new zebrafish models for studying a specific genetic form of mitochondrial disease that represents the most common cause of Leigh syndrome. The findings were recently published in the journal Human Molecular Genetics.

Genetics 63

Genetics Development Research Drugs 63

FDA Law Blog

DECEMBER 13, 2023

Sasinowski — On December 12, 2023, FDA announced the creation of a new advisory committee specifically for treatments for genetic metabolic diseases, the Genetic Metabolic Diseases Advisory Committee, or “GeMDAC.” There are hundreds of known genetic metabolic diseases, most of which are rare and carry significant morbidity.

Genetics 59

Genetics Production Development Drugs 59

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

Pharmaceutical Technology

JUNE 10, 2023

CIGB-128 is under clinical development by Center for Genetic Engineering and Biotechnology and currently in Phase I for Brain Tumor. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Buy the report here.

Genetic Engineering 100

Genetic Engineering Engineer Genetics Clinical Trials 100

pharmaphorum

MARCH 21, 2022

Neuroscience is arguably the next great frontier in medicine and 2022 dawned with a wave of exhilarating progress for the neurodegenerative drug development community. A startup led by Novartis veteran raises $80 million to develop treatments for people with degenerative brain conditions.

Genetics 52

Genetics Development Drugs Gene Therapy 52

Drug Discovery World

JANUARY 19, 2024

UK scientists have uncovered the interplay between cancer-driving genetic mutations and inherited genetic variants in a rare type of blood cancer. In the future, this knowledge could aid drug development and interventions that reduce the risk of disease.

Genetics 59

Genetics Gene DNA Development 59

Outsourcing Pharma

FEBRUARY 24, 2022

The pharmaceutical companyâs Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a âstate-of-the-artâ facility.

Genetics 52

Genetics Medicine Development RNA 52

Bio Pharma Dive

DECEMBER 12, 2023

Based on the work of MIT scientists, the well-funded startup is developing ways to insert large sizes of genetic material anywhere in the genome without damaging or breaking DNA.

Genome 326

Genome Genomics DNA Genetics 326

XTalks

MARCH 28, 2024

Duvyzat, a histone deacetylase (HDAC) inhibitor that works to reduce inflammation and muscle loss, is the first nonsteroidal drug approved to treat patients with all genetic variants of DMD. Progressive muscle weakness in the disease is caused by genetic mutations in the dystrophin gene that lead to a lack of functional dystrophin protein.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105